CompaniesMimetogen Pharmaceuticals

Mimetogen Pharmaceuticals

defunct
About

Defunct Company

Areas of Focus

Categories

Bankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (6)
View all

Total Trials

6

As Lead Sponsor

6

As Collaborator

0

Total Enrollment

2,647

By Phase

PHASE3: 5PHASE2: 1

By Status

COMPLETED: 6
Clinical Trials Pipeline6 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Today
Hover over trial bars to see details

Recent Trials

NCT05848128Lead Sponsor
Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
PHASE3Completed
642 participants
Started: Jun 28, 2023 · Completed: May 11, 2024
NCT03925727Lead Sponsor
Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
PHASE3Completed
623 participants
Started: Mar 28, 2019 · Completed: Jun 11, 2020
NCT02665234Lead Sponsor
A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease
PHASE3Completed
400 participants
Started: Jan 31, 2016 · Completed: Mar 31, 2017
NCT02634853Lead Sponsor
A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye
PHASE3Completed
429 participants
Started: Dec 31, 2015 · Completed: Mar 31, 2017
NCT01960010Lead Sponsor
A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye
PHASE3Completed
403 participants
Started: Oct 31, 2013 · Completed: Aug 31, 2014
View all 6 trials →